Ciprofloxacin, Ear Drops
Recommended OtherAuthority RequiredNot applicable line
Treatment of chronic suppurative otitis media (CSOM) in an Aboriginal and Torres Strait Islander person aged one year and older.
1
Submissions
2006–06
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2007 Recommended Antibiotic no PSD
Access path
- Jul 2006Recommended · restricted
vs Sofradex (dexamethasone with framycetin sulfate and…
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis: incremental cost-effectiveness ratios stated as $10.30 saved per week of earlier resolution (rural) and $23.40 saved per week of earlier resolution (urban). No QALY-based ICER calculated.
The incremental cost-effectiveness ratios are $10.30 saved per week of earlier resolution gained and $23.40 saved per week of earlier resolution in the rural and urban environments, respectively. PBAC · 2006
Surrogate endpoint
Decision context
PopulationAboriginal and Torres Strait Islander children under 15 years with CSOM
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2006 | Recommended · restricted | Sofradex (dexamethasone with framycetin sulfate and gramicidin) | — | RCT, Registry, Cost-minimisation · Clinical cure of discharge at 1-2 weeks |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts subsidy to Aboriginal and Torres Strait Islander persons; TGA label covers all eligible age groups without ethnic restriction.